In a historic first for perioperative oncology, Johnson & Johnson's apalutamide slashed metastasis risk by 20% and achieved near-complete cancer clearance nine times more often than standard hormone therapy alone.
Johnson & Johnson has made one of the most closely watched oncology announcements from ASCO 2026, reporting that its prostate cancer therapy ERLEADA, also known as apalutamide, significantly reduced the risk of metastasis or death when used before and after surgery. The results come from the Phase 3 PROTEUS study, a large randomized trial involving patients with high-risk localized or locally advanced prostate cancer who were eligible for radical prostatectomy. For decades, surgery has remained a core treatment option for these patients, but recurrence after surgery has continued to be a major clinical challenge. Johnson & Johnson’s new data suggest that adding systemic therapy earlier may help change that treatment pathway.
In the PROTEUS study, patients received ERLEADA plus androgen deprivation therapy for six months before surgery and six months after surgery. The trial met both of its primary endpoints: pathologic complete response or minimal residual disease at surgery, and metastasis-free survival. Patients treated with ERLEADA plus hormone therapy were nine times more likely to have little to no cancer remaining at the time of surgery, with a response rate of 8.9% compared with 1.0% for hormone therapy alone. The combination also lowered the risk of metastasis or death by 20%, a meaningful result for a patient group at high risk of disease recurrence and progression.
Explore BIS Research’s Hormone Sensitive Advanced Prostate Cancer Market report for deeper treatment-market insights.
The findings are important because high-risk localized prostate cancer can appear treatable with surgery, yet microscopic disease may remain and later lead to relapse. Johnson & Johnson reported that patients receiving the ERLEADA-based regimen went more than six years before needing subsequent therapy, compared with about three and a half years for those receiving hormone therapy alone. The study also showed a 29% reduction in the risk of disease recurrence or death and improvement in time to distant metastasis. These results position ERLEADA as a potential perioperative treatment option that could support surgery rather than replace it.
For broader disease-progression analysis, see BIS Research’s Metastatic Castration-Sensitive Prostate Cancer Market report.
The data were selected to open the plenary session at the 2026 American Society of Clinical Oncology Annual Meeting and were published simultaneously in The New England Journal of Medicine, highlighting their clinical relevance. However, Johnson & Johnson has clarified that ERLEADA plus hormone therapy is not yet approved by regulators for this earlier prostate cancer setting. Safety findings were generally consistent with previous ERLEADA studies, though higher rates of grade 3 or 4 adverse events and treatment discontinuations were reported in the ERLEADA group. Even with that caution, the PROTEUS results mark a significant development in prostate cancer care and could push oncologists toward treating aggressive disease earlier, before it spreads.
Want to know more about Prostate Cancer Testing Market.
Explore our LinkedIn Newsletter on ASCO 2026 and the next chapter of patient-centered oncology care in this article: Read more here
